Cargando…
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
BACKGROUND: There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still...
Autores principales: | Smith-Apeldoorn, Sanne Y., Veraart, Jolien K. E., Kamphuis, Jeanine, van Asselt, Antoinette D. I., Touw, Daan J., aan het Rot, Marije, Schoevers, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884875/ https://www.ncbi.nlm.nih.gov/pubmed/31783823 http://dx.doi.org/10.1186/s12888-019-2359-1 |
Ejemplares similares
-
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2020) -
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022) -
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2021) -
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
por: Breeksema, Joost J., et al.
Publicado: (2023) -
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review
por: Veraart, Jolien K E, et al.
Publicado: (2021)